Skip to main content
Ryan M. Rourke Reed

Ryan M. Rourke Reed

Edwards Wildman Palmer LLP
Associate
Search Me on: Edwards Wildman

Results for: Ryan M. Rourke Reed

    • Boston Tel +1 617 239 0580 | Fax +1 866 492 3058

    Edwards Wildman Client Advisory: SEC Advises Issuers to Continue to Comply with Conflict Minerals Rule ...

    Ryan joined the firm’s Boston office in 2011 as an associate in the Business Law Department. He represents private equity firms, public and private companies and investors in a broad range of strategic transactions. His practice focuses on private equity, venture capital, mergers and acquisitions, SEC reporting compliance and general corporate representation. 

    Notable experience includes representation of:

    • Enanta Pharmaceuticals, Inc. in its initial public offering of common stock.
    • RCN Telecom Services, LLC in its Rule 144A and Regulation S Senior Note Offering.
    • FoodShouldTasteGood, Inc., a natural foods maker, in its sale to General Mills, Inc.
    • OPNET Technologies, Inc. in its strategic acquisition of Clarus Systems, Inc.
    • Innovent Biologics, Inc., a Chinese biopharmaceutical company in multiple venture financing rounds.
    • Columbia Capital, in its strategic investment in IntelliBatt, a California-based battery back-up and predictive services company.
    • Archimedes Systems, Inc., a personal financial planning company, in its sale to Wealth Management Systems Inc.

    Featured Experience

    • Dyax Corp. Registered Direct Offering

      Our Business Law lawyers represented Dyax Corp. in its $30,000,000 registered direct offering (RDO) to existing institutional investors. MORE

    • Enanta Closes IPO

      In 2013, our Business Law lawyers represented Enanta Pharmaceuticals, in its initial public offering (IPO), which raised $64 million for Enanta's development of new compounds for combination treatment regimens for Hepatitis C.  MORE

    • Stemline Therapeutics, Inc IPO

      In January 2013, Edwards Wildman corporate, finance, insurance and intellectual property team members from Boston and Chicago advised Stemline Therapeutics, Inc. on its Initial Public Offering. MORE

    • Dyax Corp. Registered Direct Offering

      Our Business Law lawyers represented Dyax Corp. in its $30,000,000 registered direct offering (RDO) to existing institutional investors. MORE

    • Enanta Closes IPO

      In 2013, our Business Law lawyers represented Enanta Pharmaceuticals, in its initial public offering (IPO), which raised $64 million for Enanta's development of new compounds for combination treatment regimens for Hepatitis C.  MORE

    • Stemline Therapeutics, Inc IPO

      In January 2013, Edwards Wildman corporate, finance, insurance and intellectual property team members from Boston and Chicago advised Stemline Therapeutics, Inc. on its Initial Public Offering. MORE

    • Dyax Corp. Registered Direct Offering

      Our Business Law lawyers represented Dyax Corp. in its $30,000,000 registered direct offering (RDO) to existing institutional investors. MORE

    • Enanta Closes IPO

      In 2013, our Business Law lawyers represented Enanta Pharmaceuticals, in its initial public offering (IPO), which raised $64 million for Enanta's development of new compounds for combination treatment regimens for Hepatitis C.  MORE

    • Stemline Therapeutics, Inc IPO

      In January 2013, Edwards Wildman corporate, finance, insurance and intellectual property team members from Boston and Chicago advised Stemline Therapeutics, Inc. on its Initial Public Offering. MORE

    • Pacific Consolidated Industries LLC Management Buyout

      In December 2012, our lawyers represented Pacific Consolidated Industries LLC in its sale to PCI Holding Company, Inc. MORE

    • Dyax Corp. Registered Direct Offering

      Our Business Law lawyers represented Dyax Corp. in its $30,000,000 registered direct offering (RDO) to existing institutional investors. MORE

    • Enanta Closes IPO

      In 2013, our Business Law lawyers represented Enanta Pharmaceuticals, in its initial public offering (IPO), which raised $64 million for Enanta's development of new compounds for combination treatment regimens for Hepatitis C.  MORE

    • Stemline Therapeutics, Inc IPO

      In January 2013, Edwards Wildman corporate, finance, insurance and intellectual property team members from Boston and Chicago advised Stemline Therapeutics, Inc. on its Initial Public Offering. MORE

    • Stemline Therapeutics, Inc IPO

      In January 2013, Edwards Wildman corporate, finance, insurance and intellectual property team members from Boston and Chicago advised Stemline Therapeutics, Inc. on its Initial Public Offering. MORE

    Before Edwards Wildman

    Before joining the Firm, Ryan was a summer clerk for the Honorable Mary Orfanello in the Quincy District Court, researching Massachusetts civil and criminal law for judicial opinions and attending daily court sessions. At Boston College Law School, Ryan served as Articles Editor of the Boston College International and Comparative Law Review. In addition, Ryan was the Donations and Accounting Manager for the Maranyundo Initiative, a non-profit, middle school for young women in Nyamata, Rwanda. He currently is a member of the Maranyundo Initiative’s Board of Advocates. Before law school, Ryan was a teacher at the Paraclete Academy, an afterschool program in South Boston, MA. 

    Besides Edwards Wildman

    Ryan is an enthusiastic fan of the Notre Dame Fighting Irish football team, having attended at least 40 games in the last 10 years. When not in the office or at a Notre Dame game, Ryan can be found spending time with his family and close friends.

    Education +-

    Admissions+-

    Memberships+-

    The hiring of a lawyer is an important decision that should not be based solely on advertisements. Prior results do not guarantee a similar outcome.